Claim OwnershipAI in Healthcare and Life Sciences Podcast
Subscribed: 21Played: 92
Subscribe
© 2024
Description
The AI in Healthcare and Life Sciences is for non-technical leaders interested in where AI is creating an impact for patients, for business workflows, and for the bottom line.
Global Fortune 500 healthcare and life sciences leaders join Emerj AI Research team (and CEO Daniel Faggella) to share where they're seeing AI impact today, as well as best-practices for AI adoption and ROI measurement in healthcare and pharma.
Visit our advertising page to learn more about reaching our executive audience of AI adopters in the world's largest banking and insurance firms: https://emerj.com/advertise
Global Fortune 500 healthcare and life sciences leaders join Emerj AI Research team (and CEO Daniel Faggella) to share where they're seeing AI impact today, as well as best-practices for AI adoption and ROI measurement in healthcare and pharma.
Visit our advertising page to learn more about reaching our executive audience of AI adopters in the world's largest banking and insurance firms: https://emerj.com/advertise
26 Episodes
Reverse
Today's guest is Alister Campbell, Vice President, Global Head of Science and Technology at Dotmatics. Campbell works at the intersection of scientific R&D, data strategy, and applied AI across the drug discovery lifecycle. Alister joins Emerj Client Narrative & Content Strategy Lead Nick Gertsch to discuss how data and AI are shifting pharma R&D from linear, empirical workflows toward tighter, more predictive discovery loops where experiments, simulation, and modeling inform decisions earlier and faster. If you've enjoyed or benefited from some of the insights of this episode, consider leaving us a five-star review on Apple Podcasts, and let us know what you learned, found helpful, or liked most about this show!
Today's guest is Dr. Imamu Tomlinson, CEO of Vituity and President of the Vituity Cares Foundation. Vituity is a physician-owned multispecialty partnership with 6,000+ clinicians across 690 locations. Dr. Tomlinson joins Emerj Editorial Director Marilie Fouché to unpack leadership for driving AI-enabled innovation in healthcare's slow ecosystem. Dr. Tomlinson also shares practical takeaways like channeling "disagreeableness" into questions, celebrating early data wins for buy-in, and using AI to offload transactional tasks — freeing time for empathy and human-centered decisions across 13 million annual encounters. Want to share your AI adoption story with executive peers? Click emerj.com/ex2 for more information and to be a potential future guest on Emerj's flagship 'AI in Business' podcast! Learn how brands work with Emerj and other Emerj Media options at emerj.com/ad1.
Today's guest is Yasemin Agatan, Senior Vice President of Internal Audit at AdaptHealth, a provider of home medical equipment, supplies, and related services supporting patients living at home. Yasemin brings extensive experience in audit, compliance, and operational risk management within the healthcare sector. She joins Emerj Editorial Director Matthew DeMello to discuss how enterprise leaders can leverage data and AI to improve audit workflows, enhance transparency, and manage risk more effectively. Yasemin also highlights practical approaches for organizations, including improving data visibility, implementing structured, explainable processes, and using AI to identify exceptions and inefficiencies, driving measurable gains in speed, accountability, and operational performance. Want to share your AI adoption story with executive peers? Click emerj.com/ex2 for more information and to be a potential future guest on Emerj's flagship 'AI in Business' podcast!
Today's guest is Alyssa Fenoglio, VP, Global Head of Digital Commercial at Teva Pharmaceuticals. Teva is a global pharmaceutical company delivering both generic and specialty medicines across more than 60 countries. Alyssa joins Emerj CEO and Head of Research Daniel Faggella to discuss the unique challenges of digital transformation in life sciences and how organizations can leverage data and AI to create real business impact. She also shares practical strategies for securing leadership support, linking AI pilots to measurable business outcomes, and building cross-functional teams to drive innovation responsibly and at scale. Want to share your AI adoption story with executive peers? Click emerj.com/e2 for more information and to be a potential future guest on Emerj's flagship 'AI in Business' podcast! Learn how brands work with Emerj and other Emerj Media options at emerj.com/ad1.
Internal audit sits at the crossroads of regulation, data, and business outcomes—nowhere more than in healthcare and medical devices. Yasemin Agatan, Sr. Vice President of Internal Audit at AdaptHealth, joins Emerj Editorial Director Matthew DeMello to unpack what an "AI-ready" audit looks like in one of the most complex and regulated environments. Yasemin lays out today's top pressures: rapidly shifting FDA and HIPAA requirements, thorny revenue recognition and reimbursement models, multi-party contracts, and a deluge of device and platform data. She then maps where AI is already moving the needle—NLP for coding accuracy, automated claims checks, anomaly detection that shortens audit cycles—and how internal audit can lead with governance: creating an AI inventory, partnering with InfoSec, compliance, legal, and data teams, and putting privacy and data minimization at the core. Want to share your AI adoption story with executive peers? Click emerj.com/expert2 for more information and to be a potential future guest on the 'AI in Business' podcast! If you've enjoyed or benefited from some of the insights of this episode, consider leaving us a five-star review on Apple Podcasts, and let us know what you learned, found helpful, or liked most about this show!
In this episode of the AI in Healthcare and Life Sciences podcast, host Matthew DeMello speaks with John-Clark Levin, Fellow at the Yorktown Institute and researcher at Kurzweil Research, about the intersection of U.S. politics, AI development, and biosecurity. Levin outlines why the coming years may prove decisive for artificial general intelligence (AGI) and how political volatility under the current administration could directly impact AI safety and regulation. He explains the unique risks of authoritarian tendencies in shaping AI policy, particularly when it comes to epistemics—how governments decide what's true and which advisors they trust. Want to share your AI adoption story with executive peers? Click emerj.com/ex2 for more information and to be a potential future guest on Emerj's flagship' AI in Business' podcast! If you've enjoyed or benefited from some of the insights of this episode, consider leaving us a five-star review on Apple Podcasts, and let us know what you learned, found helpful, or liked most about this show!
Today's guest is John-Clark Levin, Research Lead at Kurzweil Technologies. Kurzweil Technologies, Inc. (KTI) is a research and development company developing and marketing technologies in pattern recognition and artificial intelligence. In this episode, John-Clark unpacks the challenges of deploying AI in healthcare, focusing on reliability, risk tolerance, and the gap between model performance and real-world trust. He explores why even small error rates can derail adoption in high-stakes settings and how legal, institutional, and educational barriers often slow progress more than the technology itself. Want to share your AI adoption story with executive peers? Click emerj.com/ex2 for more information and to be a potential future guest on Emerj's flagship' AI in Business' podcast! If you've enjoyed or benefited from some of the insights of this episode, consider leaving us a five-star review on Apple Podcasts, and let us know what you learned, found helpful, or liked most about this show!
Today's guest is Francesco Tisiot, Field CTO at Aiven. Aiven provides fully managed, open-source data infrastructure on all major clouds. Their platform enables organizations to scale quickly, securely, and cost-effectively — freeing teams to focus on delivering AI applications and business outcomes. Francesco returns to the program to share a pragmatic perspective on AI adoption in highly regulated industries. He outlines how generative AI can eliminate repetitive tasks, accelerate decision-making, and improve employee engagement — without compromising trust or compliance. From co-pilot interfaces to human-in-the-loop models, Francesco emphasizes where AI can provide value while keeping clinicians and analysts at the center of critical decisions. The conversation also covers the pitfalls of scaling AI too quickly. Francesco breaks down the technical and economic challenges that arise when moving from small pilots to enterprise-wide deployment. He explains why foundational data architecture, clearly defined KPIs, and regulatory foresight are essential for sustainable adoption. Want to share your AI adoption story with executive peers? Click emerj.com/ex2 for more information and to be a potential future guest on Emerj's flagship' AI in Business' podcast! If you've enjoyed or benefited from some of the insights of this episode, consider leaving us a five-star review on Apple Podcasts, and let us know what you learned, found helpful, or liked most about this show!
Today's guest is Francesco Tisiot, Field CTO at Aiven. Aiven provides fully managed, open-source data infrastructure on all major clouds. Their platform enables organizations to scale quickly, securely, and cost-effectively—freeing teams to focus on delivering AI applications and business outcomes. Francesco joins Emerj Senior Editor Matthew DeMello on today's show to discuss what it takes to responsibly adopt AI in highly regulated sectors like life sciences. Francesco shares insights from working across verticals and explains why starting with a clear understanding of data boundaries is more critical than ever. Throughout the conversation, he outlines the three most important data infrastructure steps companies must take before deploying AI solutions at scale and how organizations can avoid the costly mistake of treating AI as a plug-and-play solution. Want to share your AI adoption story with executive peers? Click emerj.com/expert2 for more information and to be a potential future guest on the 'AI in Business' podcast! If you've enjoyed or benefited from some of the insights of this episode, consider leaving us a five-star review on Apple Podcasts, and let us know what you learned, found helpful, or liked most about this show!
Today's guest is Rhett Alden, Chief Technology Officer at Elsevier. Elsevier is a global leader in information analytics and academic publishing, providing trusted scientific, technical, and medical content for researchers, clinicians, and professionals. Rhett returns to the podcast to explore how AI is reshaping healthcare education by bridging the gap between emerging technologies and traditional training methods. In this episode, Rhett shares how Elsevier is applying generative AI to enhance procedural training for healthcare students and professionals while emphasizing the continued importance of human-led instruction for conceptual understanding, ethical decision-making, and patient empathy. He also discusses the increasing adoption of AI across healthcare education institutions and the need for thoughtful implementation models that preserve quality and support human connection in learning environments. Want to share your AI adoption story with executive peers? Click emerj.com/ex2 for more information and to be a potential future guest on Emerj's flagship' AI in Business' podcast!
Today's guest is Rhett Alden, Chief Technology Officer at Elsevier. Elsevier is a global leader in information analytics and academic publishing, providing trusted scientific, technical, and medical content for researchers, clinicians, and professionals. Rhett joins us on today's show to discuss how Elsevier is tackling hallucinations in AI frameworks to deliver reliable, peer-reviewed medical and scientific information. Alden explains how retrieval-augmented generation (RAG) models differ from large language models (LLMs), ensuring that AI-generated responses are grounded in verifiable, high-quality sources. He shares how Elsevier integrates precision, completeness, bias mitigation, and harm reduction into its evaluation framework, providing transparency for clinicians who depend on AI-assisted insights. If you've enjoyed or benefited from some of the insights of this episode, consider leaving us a five-star review on Apple Podcasts, and let us know what you learned, found helpful, or liked most about this show!
Today's guest is Fred Manby, CTO and Co-founder of Iambic Therapeutics. Iambic uses algorithms to drive a high-throughput experimental platform that specializes in developing new drug discovery techniques. Fred returns to the program to explore the next frontier of AI-driven drug discovery. Building on the previous discussion, this episode delves into the transformative role of automation, data generation, and predictive modeling in pharmaceutical development. This episode is sponsored by Iambic Therapeutics. Learn how brands work with Emerj and other Emerj Media options at emerj.com/ad1.
Today's guest is Fred Manby, CTO and Co-founder of Iambic Therapeutics. Iambic uses algorithms to drive a high-throughput experimental platform that specializes in developing new drug discovery techniques. Fred joins us on today's program to discuss the evolving landscape of drug discovery in life sciences. With AI playing an increasingly critical role, the conversation explores the biggest challenges facing drug discovery workflows and how life sciences leaders can better leverage data-driven tools to address them. If you've enjoyed or benefited from some of the insights of this episode, consider leaving us a five-star review on Apple Podcasts, and let us know what you learned, found helpful, or liked most about this show!
Today's guest is Ben Coverdale, Global Account Director of Life Sciences at Patsnap. Patsnap is a healthcare technology company that provides IP and R&D teams with enhanced insights to make informed and timely decisions. Using a specialized AI model and the Hiro assistant, the platform boosts productivity and reduces inefficiencies across the innovation lifecycle. Ben returns to the show to dive deeper into the real-world applications of generative AI and large language models (LLMs) that are reshaping the drug discovery landscape. He provides a closer look at use cases where AI is not just enhancing traditional processes but enabling entirely new possibilities in drug targeting and sequencing that were previously unimaginable. If you've enjoyed or benefited from some of the insights of this episode, consider leaving us a five-star review on Apple Podcasts, and let us know what you learned, found helpful, or liked most about this show!
Today's guest is Ben Coverdale, Global Account Director of Life Sciences at Patsnap. Patsnap is a healthcare technology company that provides IP and R&D teams with enhanced insights to make informed and timely decisions. Using a specialized AI model and the Hiro assistant, the platform boosts productivity and reduces inefficiencies across the innovation lifecycle. Ben joins us on today's program to explore the transformative role of generative AI and large language models (LLMs) in life sciences. His discussion with Emerj Senior Editor Matthew DeMello covers how data silos are dissolving as companies adopt integrated LLM strategies, offering new possibilities for collaboration and efficiency. Ben provides insight into the practical applications of LLMs, the promise they hold for optimizing R&D, and the potential impact on the regulatory landscape. If you've enjoyed or benefited from some of the insights of this episode, consider leaving us a five-star review on Apple Podcasts, and let us know what you learned, found helpful, or liked most about this show!
Today's guest is Rajvir Madan, Chief Digital and Information Technology Officer at Arcutis Biotherapeutics. Arcutis Biotherapeutics is a biopharmaceutical company that develops therapies for skin-related conditions. Rajvir joins us on today's show to explore the pressing challenges and exciting opportunities within the life sciences industry. From long development timelines to the complexities of regulatory submissions, Rajvir highlights why the traditional approach to bringing new treatments to market—often spanning over a decade—needs urgent rethinking. If you've enjoyed or benefited from some of the insights of this episode, consider leaving us a five-star review on Apple Podcasts, and let us know what you learned, found helpful, or liked most about this show!
Today's guest is RJ Kedziora, Co-founder, Partner, Chief Operating Officer, and Chief Technology Officer at Estenda Solutions. Estenda is a healthcare and medical custom software development, data analytics, and consulting company with 20 years of experience in digital health. RJ joins us on today's episode to explore where the industry is seeing use cases for leveraging new AI capabilities to help drive data efficiencies. Once these technologies are commonplace, RJ shares what he thinks the future of data in healthcare spaces is going to look like. To discover more AI use cases, best practice guides, white papers, frameworks, and more, join Emerj Plus at emerj.com/p1.
Today's guest is RJ Kedziora, Co-founder, Partner, and Chief Operating and Technology Officer at Estenda Solutions. Estenda is a healthcare and medical custom software development, data analytics, and consulting company with 20 years of experience in digital health. RJ joins us on today's program to talk about challenges for healthcare leaders in driving the data necessary to take advantage of these new use cases in generative AI and beyond. Throughout the episode, RJ provides measured and tested frameworks for tackling new opportunities in the standardization and interoperability of healthcare systems, especially where they intersect with the need for data sharing across the sector and what that means for HIPAA protections. To access Emerj's frameworks for AI readiness, ROI, and strategy, visit Emerj Plus at emerj.com/p1.
Today's guest is Xiong Liu, Director of Data Science and AI at Novartis. Xiong joins us on the program today to offer life sciences leaders a framework for driving meaningful data infrastructure advancements at their organizations. Xiong emphasizes the need for robust data quality, ethics considerations, and scalability to ensure practical applications in real-life use cases. Later, he highlights the importance of understanding customer perspectives, aligning business goals with AI efforts, and leveraging graph databases to manage large-scale healthcare data. If you've enjoyed or benefited from some of the insights of this episode, consider leaving us a five-star review on Apple Podcasts, and let us know what you learned, found helpful, or liked most about this show!
Today's guest is Shreyas Becker, Head of AI & Data Products, Manufacturing & Supply at Sanofi. Shreyas returns to the Emerj podcast platform to talk about best strategies for driving digital transformation in life sciences organizations. Throughout the episode, he offers cogent and tested advice through the lens of manufacturing workflows for the ends of managing up and winning executive buy-in for systems and initiatives where the road to ROI can be opaque. If you've enjoyed or benefited from some of the insights of this episode, consider leaving us a five-star review on Apple Podcasts, and let us know what you learned, found helpful, or liked most about this show!
Comments
Download from Google Play
Download from App Store
United States